BMO Capital analyst Evan David Seigerman raised the price target on Gilead Sciences (NASDAQ: GILD) to $160.00 (from $150.00) while ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE